DEFA14A: Novartis to Acquire Avidity, Spin Off Cardiology Unit

Avidity Biosciences announces a definitive merger agreement with Novartis, spinning off its early-stage precision cardiology programs.

Summary

• Avidity Biosciences, Inc. (Avidity) has entered into a definitive merger agreement with Novartis AG (Novartis), where Avidity will become an indirect wholly owned subsidiary of Novartis.
• Prior to the merger, Avidity will execute a pre-closing reorganization, spinning off its early-stage precision cardiology programs and certain collaboration agreements into a newly formed subsidiary, Bryce Therapeutics, Inc. (SpinCo).
• SpinCo will either distribute its shares to Avidity stockholders on a pro rata basis (1 share of SpinCo Common Stock per 10 shares of Avidity common stock) or be sold to a third party.
• Following the Spin-Off, Avidity will retain all other assets and liabilities and will have no continuing ownership interest in SpinCo.
• The Spin-Off includes assets that trigger a right of first negotiation with an existing collaboration partner.
• Novartis expressed excitement about partnering with Avidity to accelerate innovation for genetic neuromuscular diseases, specifically highlighting Avidity's late-stage programs in DM1, FSHD, and DMD.

Sentiment

Score: 8

Explanation: The filing conveys a strong positive sentiment regarding the strategic benefits of the merger for Avidity's RNA therapeutics platform and patient impact, as expressed by both company managements. While standard risks associated with such transactions are disclosed, the overall tone is optimistic about future innovation and market reach.

Positives

• The acquisition by Novartis provides Avidity's RNA therapeutics and AOC platform with global development and commercialization capabilities, potentially accelerating innovation for patients.
• Novartis is committed to advancing Avidity's late-stage programs in DM1, FSHD, and DMD, which are described as potential first-in-disease therapies.
• The transaction allows Avidity's early-stage precision cardiology programs to potentially thrive as an independent entity (SpinCo) or through a sale to a third party.

Risks

• The transactions are subject to significant known and unknown risks and uncertainties, including the satisfaction of customary closing conditions, regulatory approvals, and Avidity stockholder approval.
• There are risks and costs associated with the implementation of the SpinCo separation, including the ability to complete it within the anticipated timeframe or at all, and potential changes to SpinCo's business configuration.
• The sale of certain SpinCo assets is subject to a third-party right of first negotiation, which could impact the value or terms of the Spin-Off.
• There is a risk that competing offers or acquisition proposals for Avidity may emerge.
• The transactions could cause disruption to Novartis's and/or Avidity's businesses, affecting relationships with employees, business partners, or governmental entities.
• The transactions may be more expensive to complete than anticipated.
• Stockholder litigation in connection with the transactions could result in significant costs of defense, indemnification, and liability.
• Management's attention may be diverted from ongoing business operations and opportunities due to the transactions.
• Uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data, could affect product candidate success.
• Regulatory actions or delays or government regulation generally could impact the approval and commercialization of product candidates.

Future Outlook

The proposed acquisition by Novartis and the related spin-off of Avidity's early-stage precision cardiology programs are expected to proceed, subject to customary closing conditions, regulatory approvals, and stockholder approval. Novartis anticipates leveraging its global capabilities to accelerate innovation for genetic neuromuscular diseases and advance Avidity's late-stage programs (DM1, FSHD, DMD) towards potential marketing approvals and launches. SpinCo is expected to continue as a separate and independent company or be sold to a third party, with its own management team and cash balance.

Management Comments

• Sarah Boyce (Avidity CEO): 'This has been a significant day for Avidity – for our team, for our patients and for all of the people we have been working with to achieve our vision to profoundly improve peoples lives by delivering a new class of RNA therapeutics.'
• Sarah Boyce (Avidity CEO): 'We will be transparent in sharing updates as we move through this interim period until close and ask for your patience and continued focus.'
• Vasant Narasimhan (Novartis CEO): 'Yesterday marked an exciting step forward in our shared mission to reimagine medicine. On behalf of all of us at Novartis, I want to reiterate our excitement about our agreement and the opportunity to partner with you in this important work.'
• Vasant Narasimhan (Novartis CEO): 'Together, we have the potential to accelerate innovation for people living with devastating genetic neuromuscular diseases—delivering treatments that target the root causes for these conditions. Your late-stage programs in DM1, FSHD, and DMD are remarkable achievements.'
• Vasant Narasimhan (Novartis CEO): 'We are committed to advancing these potential first-in-disease therapies by leveraging our global development and commercialization capabilities, so that patients with limited options today can have hope for tomorrow.'

Industry Context

This announcement highlights the increasing strategic value of RNA therapeutics and precision medicine platforms within the biotechnology and pharmaceutical industries. Novartis's acquisition of Avidity, a leader in Antibody Oligonucleotide Conjugates (AOCs), underscores a broader industry trend towards acquiring innovative platforms and late-stage assets in specialized disease areas like genetic neuromuscular disorders. The spin-off of early-stage cardiology programs also reflects a strategy to focus core assets and potentially unlock value from non-core divisions.

Stakeholder Impact

• Shareholders: Will vote on the merger and receive either SpinCo shares or proceeds from its sale, impacting their investment structure.
• Employees: Will experience a transition period as Avidity integrates with Novartis, with resources provided for support.
• Patients: Potential for accelerated development and broader access to transformative RNA therapeutics for genetic neuromuscular diseases (DM1, FSHD, DMD).
• Business Partners: Certain collaboration partners may exercise a right of first negotiation related to SpinCo assets.

Next Steps

• Avidity will file a preliminary and definitive proxy statement with the SEC.
• The definitive proxy statement and proxy card will be delivered to Avidity stockholders.
• A special meeting of Avidity stockholders will be held to vote on the transactions.
• Novartis, Avidity, and SpinCo intend to file other relevant documents with the SEC.
• The transactions are subject to the satisfaction of customary closing conditions, including regulatory approvals and stockholder approval.
• Avidity and Novartis will continue to operate as separate and independent companies until the transaction closes.

Key Dates

Keywords

Merger, Acquisition, Spin-off, RNA Therapeutics, Precision Cardiology, Novartis, Avidity Biosciences, Corporate Governance, Biotechnology, Pharmaceuticals